Tower Research Capital (TRC)’s Windtree Therapeutics WINT Stock Holding History
Bought
Maintained
Sold
Other funds holding WINT
SM
BBA
ARTA
Tower Research Capital (TRC)'s WINT Position: Q1 2017 in Review
Tower Research Capital (TRC) sold out of Windtree Therapeutics (WINT) in Q1 2017, closing a stake of 664 shares — an estimated $1K sold.
Tower Research Capital (TRC) first reported a position in WINT in Q2 2013 and held it in 10 quarters. The position peaked at $17K in Q2 2013. 26 funds tracked by Wall St. Rank hold WINT as of Q1 2017.
- Tower Research Capital (TRC) reported no remaining Windtree Therapeutics position as of Q1 2017 after selling out during the quarter.
- Tower Research Capital (TRC) sold 664 Windtree Therapeutics shares in Q1 2017, an estimated $1K.
- Tower Research Capital (TRC) first reported a position in Windtree Therapeutics in Q2 2013 and held it in 10 quarters.
- Tower Research Capital (TRC)'s Windtree Therapeutics position peaked at $17K in Q2 2013.
- 26 funds tracked by Wall St. Rank held Windtree Therapeutics as of Q1 2017.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2017, filed 19 May 2017.